UK busi­ness sec­re­tary look­ing in­to Philip Mor­ris' pro­posed deal to ac­quire Vec­tura — re­port

4 years ago
Deals

Eli Lil­ly part­ners with Alzheimer's cen­ter for PhI­II study; New tu­ber­cu­lo­sis con­sor­tium emerges in $218M+ project

4 years ago
News Briefing

With Mod­er­na shares fly­ing at a pan­dem­ic high, the mar­ket cap has now pierced the $100B mark, leapfrog­ging ...

4 years ago
Bioregnum

Mak­ing a name for it­self in Covid-19 test­ing, Hong Kong's Pre­net­ics is the lat­est biotech SPAC merg­er — re­port

4 years ago
Financing

Gala­pa­gos dis­ap­points again as 2 key read­outs fail to gen­er­ate much en­thu­si­asm for Gilead­'s fad­ing part­ner

4 years ago
R&D

Al­ready sit­ting on a ma­jor stem cell bank, Gen­er­ate looks to grow its re­gen­er­a­tive med­i­cines busi­ness

4 years ago
Outsourcing
Manufacturing

EX­CLU­SIVE: Shape Ther­a­peu­tics rais­es $112M in bid to make RNA edit­ing — and a whole lot else — a re­al­i­ty

4 years ago
Financing
Cell/Gene Tx

Covid-19 man­u­fac­tur­ing roundup: FDA frees up more Emer­gent vac­cine dos­es; Pfiz­er and Viet­nam dis­cuss tech trans­fer ...

4 years ago
Coronavirus
Manufacturing

Covid-19 roundup: As­traZeneca hits vac­cine dis­tri­b­u­tion snag in Thai­land; Chi­na com­pletes ex­pert re­view of BioN­Tech's ...

4 years ago
Coronavirus

Ma­jor health sys­tems refuse to ad­min­is­ter Aduhelm as top FDA lead­ers meet be­hind closed doors to talk with pay­ers

4 years ago
Pharma
FDA+

A Chi­nese I/O biotech look­ing to turn around an old No­var­tis pro­gram gets a new fundraise af­ter launch­ing PhI­II study

4 years ago
Financing

A stealthy start­up is lever­ag­ing nat­ur­al killer cells with 'mem­o­ry-like' abil­i­ties to go af­ter blood can­cer and ...

4 years ago
Financing
Cell/Gene Tx

Dis­cov­ery by Shang­hai sci­en­tists in­spires new plan of AT­TEC for pro­tein degra­da­tion

4 years ago
Financing
Startups

Ad­u­canum­ab has its ap­proval — now, let cit­i­zen-sci­en­tists come to­geth­er to see if it works

4 years ago
Biotech Voices

Tom Lynch moves to re­struc­ture Fred Hutch as acad­e­mia, in­dus­try con­tin­ue to push cell ther­a­py in­to sol­id tu­mors

4 years ago
R&D

Bank­ing on shared ex­pe­ri­ences — and now a big in­vestor — with broth­er Vivek, Shankar Ra­maswamy stacks up a $100M ...

4 years ago
R&D

FDA chides Am­gen over mis­lead­ing ban­ner ad for Neu­las­ta

4 years ago
Pharma
FDA+

Tri­al soft­ware group rais­es $45M to push de­cen­tral­ized stud­ies; $120M SPAC makes its way to Nas­daq

4 years ago
News Briefing

Ri­bon Ther­a­peu­tics is look­ing to break the mold for PARP in­hibitors and has a slate of Big Phar­ma back­ers on board

4 years ago
Financing

Pri­vate in­sur­ers de­cline to cov­er Bio­gen's new Alzheimer's drug in es­ca­lat­ing stand­off — re­port

4 years ago
FDA+

FDA mulls reg­u­la­to­ry ac­tion on Sprout's 'fe­male Vi­a­gra' af­ter ad­verse events spike

4 years ago
Pharma
FDA+

EU set to launch full-scale in­ves­ti­ga­tion in­to Grail-Il­lu­mi­na deal amid an­titrust con­cerns — re­port

4 years ago
Deals
FDA+

IPOs and ven­ture in­vest­ing rock on in Q2 as SPAC at­tack takes a break. But what hap­pened to the deals and M&A?

4 years ago
Bioregnum

Cor­nered by crit­ics, top FDA of­fi­cials stand by Aduhelm OK amid calls to re­form ac­cel­er­at­ed ap­proval process

4 years ago
FDA+
First page Previous page 676677678679680681682 Next page Last page
A service from the Financial Times